Bamlanivimab |
LY-3819253 |
Phase 3 Clinical |
AbCellera Biologics Inc, Eli Lilly And Company |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections |
Details
|
mRNA-1273.231 |
mRNA-1273.231 |
Phase 3 Clinical |
Moderna Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
mRNA-1273.815 |
mRNA-1273.815 |
Phase 3 Clinical |
Moderna Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Riltozinameran |
|
Phase 3 Clinical |
Biontech Se, Pfizer Inc |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
pemivibart |
VYD222; VYD-222 |
Phase 3 Clinical |
|
Coronavirus Disease 2019 (COVID-19) |
Details
|
abdavomeran |
BNT162b1 |
Phase 3 Clinical |
Biontech Se |
Respiratory Tract Infections; RNA Virus Infections; Drug-Related Side Effects and Adverse Reactions; Virus Diseases; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
GSK-4362620A |
GSK-4362620A |
Phase 3 Clinical |
Medicago Inc, Gsk Vaccines Gmbh |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ogalvibart/Crexavibart |
BMS-986414 + BMS-986413 |
Phase 3 Clinical |
The Rockefeller University, Bristol Myers Squibb Srlcompany |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections |
Details
|
Imdevimab |
RG-6412 |
Phase 3 Clinical |
F. Hoffmann-La Roche Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Simaravibart |
MAD-0004J08 |
Phase 3 Clinical |
Fondazione Toscana Life Sciences |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ABP-300 |
ABP-300; MW-05(Mabwell/Abpro) |
Phase 3 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd, Abpro Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ensovibep |
MP-0420 |
Phase 3 Clinical |
Molecular Partners Ag |
Coronavirus Disease 2019 (COVID-19) |
Details
|
PTX-COVID19-B |
|
Phase 3 Clinical |
Providence Therapeutics Holdings Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Amubarvimab |
BRII-196; BRII196 |
Phase 3 Clinical |
Brii Biosciences (Beijing) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Romlusevimab |
BRII198; BRII-198 |
Phase 3 Clinical |
Brii Biosciences (Beijing) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Upanovimab |
HB-27; SCTA-01 |
Phase 3 Clinical |
SinoCelltech Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
STI-2099 |
STI-2099 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SA-55 |
SA55; SA-55; BD55-5514 |
Phase 2 Clinical |
Sinovac Biotech Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Reluscovtogene ralaplasmid |
INO-4800; INO4800; PGX-9501 |
Phase 2 Clinical |
Inovio Pharmaceuticals Inc |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B |
Details
|
SARS-CoV-2 mRNA Vaccine(Argorna) |
RBMRNA-176 |
Phase 2 Clinical |
Argorna Pharmaceuticals Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Sipavibart |
AZD-3152; AZD3152 |
Phase 2 Clinical |
Astrazeneca Plc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Recombinant SARS-CoV-2 Vaccine(variant)(Shanghai Zerun) |
|
Phase 2 Clinical |
Shanghai Zerun Biotechnology Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
HY-3000 |
HY-3000 |
Phase 2 Clinical |
Hybio Pharmaceutical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Betuvax-CoV-2 |
|
Phase 2 Clinical |
Human Stem Cells Institute, Russia |
Coronavirus Disease 2019 (COVID-19) |
Details
|
FBR-002 |
FBR-002 |
Phase 2 Clinical |
Fabentech |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IBIO123 |
IBIO-123 |
Phase 2 Clinical |
Immune Biosolutions Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Bebtelovimab |
LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 |
Phase 2 Clinical |
Eli Lilly And Company |
Coronavirus Disease 2019 (COVID-19) |
Details
|
AKS-452-X |
AKS-452-X; AKS-452X |
Phase 2 Clinical |
Akston Biosciences Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Casirivimab |
RG-6413 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
LY-CovMab |
LY-CovMab |
Phase 2 Clinical |
Luye Pharma Group Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
COR-101 |
STE90-C11 |
Phase 2 Clinical |
Corat Therapeutics Gmbh |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GLS-5310 |
GLS-5310 |
Phase 2 Clinical |
Geneone Life Science Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
BGB-DXP604 |
DXP-604 |
Phase 2 Clinical |
Beigene Ltd, Singlomics Biopharmaceuticals Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Lomtegovimab |
BI-767551 |
Phase 2 Clinical |
German Center For Infection Research, University Of Cologne |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) |
|
Phase 2 Clinical |
Universidad De Costa Rica |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ChulaCov19 mRNA vaccine |
|
Phase 2 Clinical |
Chulalongkorn University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MW-33 |
MW-33; 9MW3311; 9-MW3311; 9MW-3311; 9-MW-3311 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
DXP-593 |
BGB DXP593; DXP-593 |
Phase 2 Clinical |
Singlomics Biopharmaceuticals Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Etesevimab |
LY-3832479; LY-CoV016; JS-016 |
Phase 2 Clinical |
Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd |
Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome |
Details
|
AVACC-10 |
AVACC-10 |
Phase 1 Clinical |
Intravacc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
BAT-2022 |
BAT-2022 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SCB-2020S |
SCB-2020S |
Phase 1 Clinical |
Clover Biopharmaceuticals Aus Pty Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IN-006 |
IN-006 |
Phase 1 Clinical |
Celltrion Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IMM-BCP-01 |
IMM-BCP-01 |
Phase 1 Clinical |
Immunome Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
RBMRNA-405 |
RBMRNA-405 |
Phase 1 Clinical |
Argorna Pharmaceuticals Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GB-0669 |
GB-0669 |
Phase 1 Clinical |
Generate Biomedicines Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
PA-001(PeptiDream) |
|
Phase 1 Clinical |
Peptidream |
Coronavirus Disease 2019 (COVID-19) |
Details
|
REGN17092 |
REGN-17092; REGN17092 |
Phase 1 Clinical |
|
|
Details
|
B/HPIV3/S-6P |
B/HPIV-3/S-6-P |
Phase 1 Clinical |
National Institutes Of Health |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
F-61 |
F-61 |
Phase 1 Clinical |
Wuhan Institute Of Biological Products Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-918 |
GRT-R918; GRT-R-918 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-914 |
GRT-R914; GRT-R-914 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-912 |
GRT-R912; GRT-R-912 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MTx-COVAB36 |
MTx-COVAB36 |
Phase 1 Clinical |
Memo Therapeutics AG |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Gorivitug |
REGN-15160 |
Phase 1 Clinical |
|
Coronavirus Disease 2019 (COVID-19) |
Details
|
SI-F019 |
SI-F019; F-019; SZ-F019 |
Phase 1 Clinical |
|
|
Details
|
CG-SpikeDown |
|
Phase 1 Clinical |
Caregen Co Ltd |
|
Details
|
CT-P63 |
CT-P-63; CT-P63 |
Phase 1 Clinical |
Celltrion Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
JS-026 |
JS-026 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ChAd-triCoV |
ChAd-triCoV |
Phase 1 Clinical |
Canadian Institutes Of Health Research (Cihr), Mcmaster University |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
Ad5-triCoV/Mac |
Ad5-triCoV/Mac |
Phase 1 Clinical |
Canadian Institutes Of Health Research (Cihr), Mcmaster University |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
JMB-2002 |
JMB-2002 |
Phase 1 Clinical |
Jiangxi Jemincare Group Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ogalvibart |
BMS-986414 |
Phase 1 Clinical |
Bristol Myers Squibb Srlcompany, The Rockefeller University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Crexavibart |
C144-LS; C144LS; BMS-986413 |
Phase 1 Clinical |
The Rockefeller University, Bristol Myers Squibb Srlcompany |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ABBV-47D11 |
HBM9022; ABBV-47D11; HBM-9022; 47D11 |
Phase 1 Clinical |
Abbvie Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Enuzovimab |
HFB-3013; HFB30132A |
Phase 1 Clinical |
HiFiBiO Therapeutics |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ADM-03820 |
|
Phase 1 Clinical |
Ology Bioservices Inc |
Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome |
Details
|
HLX-71 |
HLX-71 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Anti-SARS-CoV-2 IgY (Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Bamlanivimab |
LY-3819253 |
Phase 3 Clinical |
AbCellera Biologics Inc, Eli Lilly And Company |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections |
Details
|
mRNA-1273.231 |
mRNA-1273.231 |
Phase 3 Clinical |
Moderna Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
mRNA-1273.815 |
mRNA-1273.815 |
Phase 3 Clinical |
Moderna Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Riltozinameran |
|
Phase 3 Clinical |
Biontech Se, Pfizer Inc |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
pemivibart |
VYD222; VYD-222 |
Phase 3 Clinical |
|
Coronavirus Disease 2019 (COVID-19) |
Details
|
abdavomeran |
BNT162b1 |
Phase 3 Clinical |
Biontech Se |
Respiratory Tract Infections; RNA Virus Infections; Drug-Related Side Effects and Adverse Reactions; Virus Diseases; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
GSK-4362620A |
GSK-4362620A |
Phase 3 Clinical |
Medicago Inc, Gsk Vaccines Gmbh |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ogalvibart/Crexavibart |
BMS-986414 + BMS-986413 |
Phase 3 Clinical |
The Rockefeller University, Bristol Myers Squibb Srlcompany |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections |
Details
|
Imdevimab |
RG-6412 |
Phase 3 Clinical |
F. Hoffmann-La Roche Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Simaravibart |
MAD-0004J08 |
Phase 3 Clinical |
Fondazione Toscana Life Sciences |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ABP-300 |
ABP-300; MW-05(Mabwell/Abpro) |
Phase 3 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd, Abpro Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ensovibep |
MP-0420 |
Phase 3 Clinical |
Molecular Partners Ag |
Coronavirus Disease 2019 (COVID-19) |
Details
|
PTX-COVID19-B |
|
Phase 3 Clinical |
Providence Therapeutics Holdings Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Amubarvimab |
BRII-196; BRII196 |
Phase 3 Clinical |
Brii Biosciences (Beijing) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Romlusevimab |
BRII198; BRII-198 |
Phase 3 Clinical |
Brii Biosciences (Beijing) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Upanovimab |
HB-27; SCTA-01 |
Phase 3 Clinical |
SinoCelltech Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
STI-2099 |
STI-2099 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SA-55 |
SA55; SA-55; BD55-5514 |
Phase 2 Clinical |
Sinovac Biotech Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Reluscovtogene ralaplasmid |
INO-4800; INO4800; PGX-9501 |
Phase 2 Clinical |
Inovio Pharmaceuticals Inc |
Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B |
Details
|
SARS-CoV-2 mRNA Vaccine(Argorna) |
RBMRNA-176 |
Phase 2 Clinical |
Argorna Pharmaceuticals Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Sipavibart |
AZD-3152; AZD3152 |
Phase 2 Clinical |
Astrazeneca Plc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Recombinant SARS-CoV-2 Vaccine(variant)(Shanghai Zerun) |
|
Phase 2 Clinical |
Shanghai Zerun Biotechnology Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
HY-3000 |
HY-3000 |
Phase 2 Clinical |
Hybio Pharmaceutical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Betuvax-CoV-2 |
|
Phase 2 Clinical |
Human Stem Cells Institute, Russia |
Coronavirus Disease 2019 (COVID-19) |
Details
|
FBR-002 |
FBR-002 |
Phase 2 Clinical |
Fabentech |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IBIO123 |
IBIO-123 |
Phase 2 Clinical |
Immune Biosolutions Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Bebtelovimab |
LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 |
Phase 2 Clinical |
Eli Lilly And Company |
Coronavirus Disease 2019 (COVID-19) |
Details
|
AKS-452-X |
AKS-452-X; AKS-452X |
Phase 2 Clinical |
Akston Biosciences Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Casirivimab |
RG-6413 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
LY-CovMab |
LY-CovMab |
Phase 2 Clinical |
Luye Pharma Group Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
COR-101 |
STE90-C11 |
Phase 2 Clinical |
Corat Therapeutics Gmbh |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GLS-5310 |
GLS-5310 |
Phase 2 Clinical |
Geneone Life Science Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
BGB-DXP604 |
DXP-604 |
Phase 2 Clinical |
Beigene Ltd, Singlomics Biopharmaceuticals Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Lomtegovimab |
BI-767551 |
Phase 2 Clinical |
German Center For Infection Research, University Of Cologne |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) |
|
Phase 2 Clinical |
Universidad De Costa Rica |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ChulaCov19 mRNA vaccine |
|
Phase 2 Clinical |
Chulalongkorn University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MW-33 |
MW-33; 9MW3311; 9-MW3311; 9MW-3311; 9-MW-3311 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
DXP-593 |
BGB DXP593; DXP-593 |
Phase 2 Clinical |
Singlomics Biopharmaceuticals Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Etesevimab |
LY-3832479; LY-CoV016; JS-016 |
Phase 2 Clinical |
Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd |
Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome |
Details
|
AVACC-10 |
AVACC-10 |
Phase 1 Clinical |
Intravacc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
BAT-2022 |
BAT-2022 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SCB-2020S |
SCB-2020S |
Phase 1 Clinical |
Clover Biopharmaceuticals Aus Pty Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IN-006 |
IN-006 |
Phase 1 Clinical |
Celltrion Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
IMM-BCP-01 |
IMM-BCP-01 |
Phase 1 Clinical |
Immunome Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
RBMRNA-405 |
RBMRNA-405 |
Phase 1 Clinical |
Argorna Pharmaceuticals Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GB-0669 |
GB-0669 |
Phase 1 Clinical |
Generate Biomedicines Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
PA-001(PeptiDream) |
|
Phase 1 Clinical |
Peptidream |
Coronavirus Disease 2019 (COVID-19) |
Details
|
REGN17092 |
REGN-17092; REGN17092 |
Phase 1 Clinical |
|
|
Details
|
B/HPIV3/S-6P |
B/HPIV-3/S-6-P |
Phase 1 Clinical |
National Institutes Of Health |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
F-61 |
F-61 |
Phase 1 Clinical |
Wuhan Institute Of Biological Products Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-918 |
GRT-R918; GRT-R-918 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-914 |
GRT-R914; GRT-R-914 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GRT-R-912 |
GRT-R912; GRT-R-912 |
Phase 1 Clinical |
Gritstone Bio Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MTx-COVAB36 |
MTx-COVAB36 |
Phase 1 Clinical |
Memo Therapeutics AG |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Gorivitug |
REGN-15160 |
Phase 1 Clinical |
|
Coronavirus Disease 2019 (COVID-19) |
Details
|
SI-F019 |
SI-F019; F-019; SZ-F019 |
Phase 1 Clinical |
|
|
Details
|
CG-SpikeDown |
|
Phase 1 Clinical |
Caregen Co Ltd |
|
Details
|
CT-P63 |
CT-P-63; CT-P63 |
Phase 1 Clinical |
Celltrion Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
JS-026 |
JS-026 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ChAd-triCoV |
ChAd-triCoV |
Phase 1 Clinical |
Canadian Institutes Of Health Research (Cihr), Mcmaster University |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
Ad5-triCoV/Mac |
Ad5-triCoV/Mac |
Phase 1 Clinical |
Canadian Institutes Of Health Research (Cihr), Mcmaster University |
Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections |
Details
|
JMB-2002 |
JMB-2002 |
Phase 1 Clinical |
Jiangxi Jemincare Group Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ogalvibart |
BMS-986414 |
Phase 1 Clinical |
Bristol Myers Squibb Srlcompany, The Rockefeller University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Crexavibart |
C144-LS; C144LS; BMS-986413 |
Phase 1 Clinical |
The Rockefeller University, Bristol Myers Squibb Srlcompany |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ABBV-47D11 |
HBM9022; ABBV-47D11; HBM-9022; 47D11 |
Phase 1 Clinical |
Abbvie Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Enuzovimab |
HFB-3013; HFB30132A |
Phase 1 Clinical |
HiFiBiO Therapeutics |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ADM-03820 |
|
Phase 1 Clinical |
Ology Bioservices Inc |
Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome |
Details
|
HLX-71 |
HLX-71 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Anti-SARS-CoV-2 IgY (Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Coronavirus Disease 2019 (COVID-19) |
Details
|